Psychedelics w/ Hamilton Morris: 5CAST w/ Andrew Callaghan (#12)

Hamilton Morris joins host Andrew Callaghan on 5CAST to examine corporate conflict, media narratives, and regulatory decisions shaping the modern psychedelic ecosystem. Morris details how the activist group Psymposia, corporate entities, and media figures targeted MAPS and contributed to the FDA's rejection of MDMA-assisted therapy. He argues that bad-faith critiques, patent panic, and corporate infighting derail genuine drug policy reform and public access to useful medical treatments. The conversation also explores drug prohibition, Hallucinogen Persisting Perception Disorder (HPPD), the synthesis of novel compounds, and Hamilton's experience producing journalism at Vice Media.